A phase II/III trial (NCT03470922) evaluating the combination versus nivolumab alone in advanced melanoma showed a median progression-free survival (mPFS) of 10.1 months with the combination versus 4.6 months with nivolumab alone, indicating a greater benefit in progression-free survival with dual inhibition of LAG-3 and PD-1 in patients with metastatic or unresectable melanoma (Table 1) (10). The gene discussed is LAG3; the disease is melanoma.